Cite
HARVARD Citation
Elyashiv, O. et al. (2021). ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum‐sensitive ovarian cancer following a response to platinum‐based chemotherapy. International journal of gynecological cancer. 31 (1), p. . [Online].